Therefore, while preclinical data indicate that AXL is a promising therapeutic target, particularly within docetaxel-resistant disease, more research is required to establish the role of AXL activation in prostate cancer, and to determine whether PTEN status is a predictive marker for AXL activity. The gene discussed is AXL; the disease is Familial prostate cancer.